Kornimate/medical-research-clean huggingface dataset:
finnish spinal cord injury study (finsci)

Conditions: Spinal Cord Injuries; Health, Subjective

Summary: the purpose of the finnish spinal cord injury study (finsci) is to identify factors related to the health and functioning of people with spinal cord injury (sci), their challenges with accessibility and how such factors are interconnected. the international classification of functioning, disability and health (icf) is used in the study as a structured framework. the study participants will be recruited from three sci outpatient clinics, which together are responsible for the life-time care of the sci population in finland. mixed methods are used including a questionnaire and interviews. the survey will be formed from patient-reported instruments; sci-specified spinal cord injury secondary condition scale, spinal cord independence measure, nottwil environmental factors inventory short form and selected items of the generic instruments of patient-reported outcomes measurement information system and national study of health, well-being and service. the survey covers 51 icf categories. the study results can help develop care and rehabilitation policies with sci, the planning of training models and information provided to various parties involved.

the detailed description of the protocol has been published. please, see the reference tallqvist et al.

Eligibility criteria:
inclusion criteria: * 16 years or over * traumatic or non-traumatic sci * asia-classification a,b,c tai d * time since onset of sci over 6 months * client of hus, tays or oys sci outpatient clinic exclusion criteria: * innate sci * progressive new non-traumatic sci * neurodegenerative disease * multiple sclerosis amyotrophic lateral sclerosisguillain-barre syndrome institutional care

Keywords: patient reported outcomes icf survey interview
validation of a production method of stem cell isolated from the nasal cavity for an innovative cell therapy of cleft palate

Conditions: Cleft Palate

Summary: cell therapy appears to be an alternative to treat bone defects. scientific advances have shown in animal models and in humans that mesenchymal stem cells were good candidates to support cellular bone regeneration after transplantation. however, their collection requires invasive sampling usually bone marrow. a new candidate stem cells able to stimulate bone regeneration has recently been identified in the nasal cavity, these cells are called "ecto-mesenchymal" cells. these stem cells have very similar biological characteristics of mesenchymal stem cells of bone marrow. they exhibit a high mitogenic activity and hold great potential for differentiation into osteoblast lineage. given their properties and their ease of access within the nasal cavity, ecto-mesenchymal stem cells offer new prospects for cell therapy targeting bone involvement. in this context, the ecto-mesenchymal stem cells represent a nasal bone reconstruction interesting alternative in particular in indication of the cleft. they are directly and easily accessible in these children when conventional surgical reconstruction. the investigators propose in this study to validate a production method of stem cell called "ecto-mesenchymal" isolated from a biopsy of the nasal cavity of children with cleft lip and palate to be able to soon propose cell therapy innovative in this indication.


Eligibility criteria:
inclusion criteria: * paediatric patients with unilateral cleft lip and alveolar (or maxilla) or labio-maxillo-palatal, requiring surgical management of reconstruction * children weighing more than 2 kg exclusion criteria: * children with concomitant pathology that might alter bone turnover: osteogenesis imperfecta, kidney failure, chronic inflammatory diseases, infections, other diseases
efficacy of cyclosporine ophthalmic emulsion in the treatment of dry eye syndrome in contact lens wearers

Conditions: Contact Lens Wearers With Dry Eye Syndrome

Summary: cyclosporine ophthalmic emulsion is currently used in the treatment of dry eye syndrome. contact lens wearers frequently suffer from dry eye syndrome. the purpose of this study is to evaluate cyclosporine ophthalmic emulsion verses re-wetting drops in the relief of dry eye symptoms in contact lens wearers


Eligibility criteria:
inclusion criteria: * contact lens wearer * clinical diagnosis of dry eye syndrome exclusion criteria: -

Keywords: cyclosporine, dry eye syndrome, contact lens
a metabolomics-based study to explore the mechanism of remission of metabolic syndrome radical resection of colorectal cancer

Conditions: Metabolomics

Summary: 1. analysis of preoperative and postoperative metabolite changes: through metabolomics technology, the changes of preoperative and postoperative metabolites in patients with colorectal cancer complicated with metabolic syndrome such as hypertension and diabetes were systematically analyzed, and the key metabolites related to postoperative remission were found. 2. explore the influencing factors of postoperative remission of metabolic syndrome: combined with clinical data, the association between various metabolites and the degree of postoperative remission was evaluated, and the main factors affecting postoperative remission were determined. to reveal the mechanism of the remission of metabolic syndrome after surgery: to clarify the metabolic pathways and mechanisms involved in the remission of metabolic syndrome after surgery through multi-level metabolomics analysis, and to provide a new theoretical basis for the development of tumor metabolic surgery.

this study will continue for 2-3 years. all patients who meet the inclusion and exclusion criteria will be divided into hypertension group and diabetes group according to the type of metabolic syndrome, with 120 cases in each group. blood and feces of all patients were collected before surgery, 3 days after surgery, 6 months after surgery, and 1 year after surgery. the collected samples will be subjected to untargeted metabolomics analysis, using nmr-ivdr technology to detect the dynamic changes of all small molecular metabolites (mainly endogenous small molecular compounds with relative molecular weight within 1000 da) in blood and feces before and after stimulation or disturbance without bias. the differential metabolites of blood glucose, blood lipids, cholesterol, insulin, renin, aldosterone and angiotensin were screened by bioinformatics analysis, and the pathway analysis of differential metabolites was performed to reveal the potential physiological mechanism of postoperative hypertension, diabetes and other metabolic syndrome remission

Eligibility criteria:
inclusion criteria: * 1. age \>18 years old. 2. patients with hypertension or diabetes for more than 1 year before surgery. 3. patients who planned to undergo radical resection of colorectal cancer exclusion criteria: * 1. emergency operation due to intestinal obstruction and intestinal perforation. 2. tumor with distant metastasis. 3. combined resection of other important organs. 4. severe postoperative complications. 5. patients who are using drugs that may significantly affect metabolic status (such as hormonal drugs, potent immunosuppressants, etc.). 6. incomplete clinical data.

Keywords: colorectal cancer metabolomics hypertension diabetes fatty liver
covered metallic stent and benign colonic strictures

Conditions: Colonic Diseases; Stricture; Occlusion

Summary: self-expanding metallic stent placement is a safe and effective endoscopic procedure increasingly used to relieve colonic obstruction. fully covered metal stents (fcsems) and plastic stents have been recently developed to reduce both hyperplastic (non tumoral) and tumoral tissue ingrowth. these fully covered metal or plastic stents have several advantages over non-covered stents, including the possibility of retrieval and limited local tissue reaction, while providing alleviation of obstruction at possibly lower costs. only few reports of fully covered metal stent placement in patients with benign colorectal strictures are available in the literature. the aim of this study was to assess the effectiveness of fcsems in the management of the colonic benign strictures.

it is a national multicentric retrospective study on the use of fully covered metal stent placement in patients with benign colorectal strictures. consecutive patients above 18 years of age with a symptomatic benign colonic stricture despite optimal medical and/or endoscopic dilation therapy and which required the use of a fcsems were included. all strictures were confirmed to be benign by histology. all details concerning previous history, origins and treatment (medical or endoscopic) of the colonic stenosis were collected from the medical file. senior endoscopists with an experience of more than 50 colonic stent placements performed the procedure under general propofol-induced anesthesia with the same technic (the stent was placed under fluoroscopic and videoendoscopic controls). patients were required after the procedure to take oral osmotic laxatives regularly. post-stenting complications were defined as immediate (during the procedure), early (occurring ≤ 30 days) and late (\> 30 days) after the procedure. stent removal and routine follow up endoscopy were scheduled 4 to 6 weeks after placement in most patients or earlier if complications occurred. all patients were followed up at regular intervals based on their clinical situation. a retrospective chart review was performed to analyze the long-term outcome of the patients.

Eligibility criteria:
inclusion criteria: * patients above 18 years of age * symptomatic benign colonic stricture despite optimal medical and/or endoscopic dilation therapy exclusion criteria: * previous insertion or treatment of the stricture with metallic (covered or uncovered) stent

Keywords: covered metallic stent colon benign stricture
efficacy of rectal infiltration of exparel for analgesic benefit following hemorrhoidectomy

Conditions: Hemorrhoid

Summary: the purpose of this study is to compare the quality and duration of pain relief after a hemorrhoidectomy, provided by locally administered liposomal bupivacaine versus bupivacaine hcl or control with saline. it is hypothesized that liposomal bupivacaine will provide more effective postoperative pain relief than both bupivacaine hcl and the control.


Eligibility criteria:
inclusion criteria: * patients undergoing hemorrhoidectomy for grade 3 or 4 hemorrhoids who are english-speaking patients, 21-65 yr of age, asa physical status i-iii, bmi\<30 exclusion criteria: * contraindications to administration of local anesthesia (e.g., local anesthetic allergy), difficult airway (mallampati\>2), psychiatric or cognitive disorders, pregnancy , and history of substance abuse or chronic opioid use

Keywords: liposomal bupivacaine exparel
effects of ric on cognitive function and blood oxygen levels in unacclimatized adult at high altitude

Conditions: Adult

Summary: several studies have shown cognitive impairment such as memory, perception and learning skill during ascent to high altitudes. however, few studies have directly investigated the effect of high altitudes exposure on attention-a high-level cognitive function. remote ischemic conditioning (ric) is a noninvasive and easy-to-use neuroprotective strategy, it has been proven to be an effective strategy for neuroprotection in ischemic stroke and chronic cerebral ischemia patients.

this study will provide insights into the preliminary proof of principle, safety, cognitive dysfunction and blood oxygen levels protective effects of ric in adults exposing to high altitude conditions, and this data will provide parameters for future larger scale clinical trials if efficacious.

Eligibility criteria:
inclusion criteria: * the age was between 19 and 30 years. * all participants should meet the criteria which included right-hand dominance, normal or corrected-to-normal vision. * the ric group volunteers have no history of intravascular thrombosis in the bilateral upper limbs; * the high altitude participants move into the high-altitude environment within one month, and the low altitude volunteers have long-term life in low altitude areas. exclusion criteria: * severe hepatic or renal dysfunction * severe hemostatic disorder or severe coagulation dysfunction * any of the following cardiac disease - rheumatic mitral and or aortic stenosis, prosthetic heart valves, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, patent foramen ovale, left ventricular mural thrombus or valvular vegetation, congestive heart failure, bacterial endocarditis, or any other cardiovascular condition interfering with participation * serious, advanced, or terminal illnesses with anticipated life expectancy of less than one year * patient participating in a study involving other drug or device trial study 7. patients with existing neurological or psychiatric disease that would confound the neurological or functional evaluations 8. unlikely to be available for follow-up for 3 months 9. contraindication for ric - severe soft-tissue injury, fracture, or peripheral vascular disease in the upper limbs.

Keywords: adult remote ischemic conditioning high altitude condition cognitive function blood oxygen levels
mid-term data collection of the treatment of intracranial aneurysms with the web™ aneurysm embolization system

Conditions: Ruptured and Unruptured Intracranial Aneurysms

Summary: flow disruption is a new endovascular approach for treatment of both ruptured and unruptured intracranial aneurysms, which involves placement of an endosaccular device (web) which modifies the blood flow at the level of the neck and induces intraaneurysmal thrombosis. the web was designed to treat wide-neck bifurcation aneurysms. this observational study will collect data about the routine practice in one center of using the web in ruptured and unruptured intracranial aneurysms. the primary objective is to evaluate its efficacy by assessing the anatomic outcome during follow-up.


Eligibility criteria:
inclusion criteria: 1. patient is at least 18 years old. 2. patient is capable to undergo general anaesthesia. 3. patient must sign and date the informed consent form prior to data registration. if patient is not able to give informed consent for himself/herself, a legally authorized representative must give informed consent on his/her behalf. 4. patient has a ruptured or unruptured intracranial aneurysm requiring endovascular treatment. 5. aneurysm with dome-to-neck ratio ≥ 1. 6. aneurysm size favourable for web implantation (aneurysm width \ 3mm). exclusion criteria: 1. patient is pregnant. 2. patient has renal insufficiency (grf \< 45 ml/min/1.73 m2). 3. patient is unable to comply with the study protocol (e.g. no permanent address, known to be non-compliant or presenting an unstable psychiatric history).
study of poziotinib in participants with her2-positive metastatic breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to establish the dose regimen and evaluate the preliminary efficacy and the safety/tolerability of poziotinib in participants with human epidermal growth factor receptor 2 (her2)-positive metastatic breast cancer who have received at least two prior her2-directed treatment regimens.

this is a phase 2, open-label, multicenter study to establish the dose regimen and evaluate the preliminary efficacy and the safety/tolerability of poziotinib in participants with her2-positive metastatic breast cancer who have received at least two prior her2-directed treatment regimens. each treatment cycle will be 21 days in duration. during each 21-day cycle, participants who are eligible for participation will receive poziotinib orally once daily. all treated participants will be followed up until disease progression, death, intolerable adverse events or up to a maximum of 24 months whichever comes earlier.

Eligibility criteria:
inclusion criteria: 1. histopathologically confirmed primary breast cancer with metastatic lesions. 2. confirmed her2 overexpression or gene-amplified tumor 3. at least two prior her2-directed therapy regimens for breast cancer, including trastuzumab and trastuzumab emtansine 4. measurable disease per response evaluation criteria for solid tumors version 1.1 (recist v1.1) 5. participant is at least 18, and ≤90 years of age. 6. adequate hematologic, hepatic, and renal function 7. eastern cooperative oncology group (ecog) performance status \<= 2 exclusion criteria: 1. previous treatment with poziotinib prior to study participation 2. brain metastases that are symptomatic or require therapy to control symptoms, as well as any history of radiation, surgery, or other therapy, including steroids, to control symptoms from brain metastases within 15 days of enrollment. 3. anticancer chemotherapy, biologics, immunotherapy, cure-intent radiotherapy, or investigational treatment within 15 days, except for hormone therapy, palliative therapy, or supportive therapy. 4. history of congestive heart failure class iii/iv according to the new york heart association (nyha) functional classification or serious cardiac arrhythmias requiring treatment. 5. cardiac ejection fraction \<50% 6. history of other malignancies within the last 5 years 7. participant is pregnant or breast-feeding. 8. unable to take drugs orally

Keywords: poziotinib metastatic breast cancer her2-positive pan-her inhibitor
evaluation of formin gene status and expression in myeloproliferative and myelodysplastic disorders

Conditions: Myeloproliferative Disorder; MDS; AML

Summary: aim of the study is to analyze the expression of genes and sequences encoding the human mammalian diaphanous (mdia) related formin proteins to test the hypothesis that defects in the mdia expression or function might drive the pathophysiology of myelodysplastic syndrome, acute myeloid leukemia and other myeloproliferative diseases.

leukocytes and myeloid lineage cells from these specimens will be assayed for expression of drf genes using standard molecular biological approaches to measure mrna levels. extracted dna will be analyzed for mutations that affect expressions or function using direct sequencing techniques. alternatively, expression of drf gene products (mdia proteins) will be assessed using specific antibodies and flow cytometry. molecular findings resulting from these assays will be correlated with clinical information recorded in specimen logbook.

Eligibility criteria:
inclusion criteria: * 18 and over * male * female * diagnosed with mds, mpd and aml exclusion criteria: * under the age of 18 * received bone marrow transplant control group criteria: inclusion: * healthy men and women * ≥ 55 years of age exclusion: * history of hematological condition * history of cancer

Keywords: gene expression gene sequencing gene encoding mpd mds aml mdia
pf-04856884 (cvx-060) in combination with axitinib in patients with previously treated metastatic renal cell carcinoma

Conditions: Metastatic Renal Cell Carcinoma

Summary: to evaluate the combination of pf-04856884 (cvx-060) in combination with axitinib (ag-013736) in patients that have received one prior systemic regimen for metastatic renal cell carcinoma (mrcc) vs. axitinib alone.

the study was prematurely discontinued on 06nov2012 due to tolerability findings in patients treated in part i of the study that have prompted the sponsor to re-evaluate the strategic development of the program. an unexpected frequency of arterial thrombotic events (ates) and venous thrombotic events (vtes) were reported in patients treated in part i.

Eligibility criteria:
inclusion criteria: * adult male or female patients with histologically or cytologically confirmed renal cell cancer (rcc) with a component of clear cell subtype and evidence of metastasis * evidence of unidimensionally measurable disease * prior therapy: part i: having received 1 to 3 prior systemic regimens for treatment of mrcc * part ii: evidence of disease progression following 1 prior regimen administered as 1st line therapy for mrcc. the prior regimen must have contained one of the following: vegfr2 tyrosine kinase inhibitor (tki) or other anti vegf \[vascular endothelial growth factor\] compounds, such as bevacizumab * adequate bone marrow, liver and renal function exclusion criteria: part i: * intolerant to prior ag 013736 therapy or prior treatment with compounds which contain the core platform antibody as pf 04856884 part ii: * prior ag 013736 therapy, more than one systemic first-line regimen for the treatment of mrcc and prior treatment with compounds which contain the core platform antibody as pf 04856884 * major surgery \<4 weeks or radiation therapy \<2 weeks prior to start of therapy * clinically significant gastrointestinal abnormalities * current use or anticipated need for drugs that are known potent cyp3a4 inhibitors and drugs that are known cyp3a4 or cyp1a2 inducers * history of bleeding diathesis or coagulopathy * grade 3 or greater hemorrhage from any cause \<4 weeks prior to screening; * hemoptysis \>½ teaspoon of blood per day within 2 weeks prior to screening.

Keywords: cvx-060 pf-04856884 ag-013736 axitinib mrcc metastatic renal cell cancer second line anti-angiogenic ang-2
the use of zoledronic acid to prevent cancer-treatment bone loss in post-menopausal women receiving adjuvant letrozole for breast cancer

Conditions: Breast Cancer

Summary: post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg iv 15-minute infusion every 6 months or delayed start zoledronic acid 4 mg iv 15-minute infusion every 6 months. delayed start zoledronic acid will be initiated when either the bone mineral density t-score is below -2 standard deviations at either the lumbar spine or hip or any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the month 36 scheduled visit. letrozole 2.5 mg will be given daily for 5 years.


Eligibility criteria:
inclusion criteria: * stage i-iiia breast cancer * postmenopausal * recent surgery for breast cancer exclusion criteria: * metastatic disease * invasive bilateral disease * clinical or radiological evidence of existing fracture in spine or hip other protocol-defined inclusion / exclusion criteria may apply.

Keywords: breast cancer letrozole zoledronic acid adjuvant postmenopausal
efficacy of vojta on balance and quality of life in subject with cnlbp

Conditions: Chronic Non-Specific Low Back Pain

Summary: . to investigate the effect of vojta method on static balance ,dynamic balance, quality of life in patients with chronic non - specific low back pain

this randomized controlled trial is to investigate the effect of vojta method on balance and quality of life in patients with chronic non-specific low back pain. forty patients (male and female) complaining of chronic non -specific low back pain was recruited to share in this study . the recruited patients were randomly recruited into two groups; group a (control group) and group b (study group). group a: received conventional treatment of back pain which included; tens 20 min and hot packs 10 min .the total treatment session is 30 min three session per week for four weeks group b: received conventional treatment of back pain in addition to vojta method. the total treatment session is 40 min. patient in both groups performed 10 sessions, 3 session per week

Eligibility criteria:
inclusion criteria: 1. patients with chronic non -specific low back pain for more than 3 months. 2. their age ranged between 18-35 years old 3. both sexes were recruited in this study. 4. their bmi ranged between 18-25 kg/m2 exclusion criteria: 1- patients with previous spinal surgery 2. patients who have radiological diagnosis of spondylolysis or spondylolisthesis. 3. patient with neurological disease . 4. chest problems 5. systematic disease